Campath-1H + FK506 and Methylprednisolone for GVHD
Completed · Phase 2
Conditions studied: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
In brief
RATIONALE: Alemtuzumab, tacrolimus, and methylprednisolone may be an effective treatment for graft-versus-host disease caused by a donor stem cell transplant. PURPOSE: This phase II trial is studying how well giving alemtuzumab together with tacrolimus and methylprednisolone works in treating acute graft-versus-host disease in patients who have undergone donor stem cell transplant.
Key facts
- Study ID
- NCT00109993
- Run by
- Case Comprehensive Cancer Center
- People needed
- 34
- Starts
- 2005-01-01
- Expected to finish
- 2007-05-01
- Last updated by the study team
- 2010-06-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mt. Sinai Medical Center — New York, New York, United States
- Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center — Cleveland, Ohio, United States
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center — Cleveland, Ohio, United States
- Oregon Health Sciences University — Portland, Oregon, United States
- Western Pennsylvania Hospital — Pittsburgh, Pennsylvania, United States
- Texas Transplant Institute — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.